# GeneOhm Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneohm-sciences

- Industry: Healthcare
- Headquarters: San Diego, US
- Website: www.bd.com/geneohm
- Total disclosed funding: $38M
- Latest round: Series C (Jan 18, 2005)
- Investors on record: 7

## About

GeneOhm Sciences, Inc. develops advanced molecular diagnostic solutions, primarily focusing on nucleic acid extraction and real-time polymerase chain reaction (PCR) testing to improve efficiency in laboratory environments.GeneOhm Sciences, Inc. specializes in molecular diagnostics, focusing on rapid testing solutions. In February 2006, the company was acquired by Becton, Dickinson and Company. The headquarters is located in San Diego, US. The founder's history and prior ventures are not specified. The company has engaged in 5 investment deals, with its latest funding round being Series C, where it raised USD 14.00 mn from investors including CB Health Ventures and Questmark Management Company.BD MAX™ is the flagship product of GeneOhm Sciences, Inc., a fully integrated, automated molecular platform designed for nucleic acid extraction and real-time PCR testing. The platform enhances laboratory efficiency by delivering timely and accurate results for up to 24 samples within approximately three hours. Key offerings include assays for enteric solutions, healthcare-associated infections (HAIs), women's health, and respiratory infections, catering to hospitals, clinical laboratories, and healthcare providers both in the US and internationally.BD MAX™ employs a business-to-business (B2B) model, generating revenue through direct sales agreements with healthcare providers and laboratories. Revenue streams include the sale of diagnostic systems and assays, such as the BD MAX™ Vaginal Panel and BD MAX™ MRSA XT Panel. This model ensures clients have access to specialized tests, allowing them to efficiently manage patient diagnostics while streamlining the procurement process.Looking ahead, GeneOhm Sciences, Inc. intends to launch new diagnostic products aimed at expanding its portfolio in the molecular diagnostics market. The funding from the Series C round will support these product developments and enhancements in technology. Additionally, the company is exploring opportunities to expand into new geographic markets, although specific regions have not been disclosed. The strategic growth plan aims to increase market share and improve accessibility to its diagnostic solutions.

## Funding rounds

- Series C, Jan 18, 2005, $14M — CHL Medical Partners, Domain Associates, CB Health Ventures, Questmark Management Company, CDIB BioScience Venture Management, POSCO BioVentures, Kaiser Permanente Ventures
- Series C, Nov 24, 2004, $12M — CHL Medical Partners, Domain Associates, CB Health Ventures, CDIB BioScience Venture Management
- Series B, Jan 1, 2003, $12M — CHL Medical Partners, Domain Associates, CB Health Ventures

## Investors

- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C
- CB Health Ventures (https://capitalatlas.ai/funds/cb-health-ventures) — Series B, Series C
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series C
- Questmark Management Company (https://capitalatlas.ai/funds/questmark-management-company) — Series C
- POSCO BioVentures (https://capitalatlas.ai/funds/posco-bioventures) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C